Form 144 filed by Frank Klein, an officer at Rocket Lab USA Inc. (NASDAQ: RKLB), notifies of a proposed sale of 2,546 shares of common stock through broker Morgan Stanley Smith Barney LLC, with an approximate sale date of June 9, 2025, and aggregate market value of $73,630.32 based on shares outstanding of 461,432,393. The shares were acquired on May 22, 2025, from restricted stock units issued by the company. This transaction relies on a Rule 10b5-1 trading plan established on December 13, 2024, which allows pre-scheduled sales to avoid insider trading concerns. Klein reports no knowledge of undisclosed material adverse information and lists prior sales in the past three months: 1,818 shares on June 2 ($48,193, 10b5-1), 44,885 on May 30 ($1.20M, 10b5-1), 2,569 on May 28 ($77,000, 10b5-1), 1,835 on March 17 ($36,572), and 44,553 on March 14 ($810,031). These are typical for executive compensation via equity vesting in the space industry, where Rocket Lab operates launch services and spacecraft manufacturing; such sales represent negligible dilution (<0.03% of outstanding shares).

This is a minor, pre-planned insider sale under Rule 10b5-1, likely for tax or diversification from RSU vesting, representing <0.001% of outstanding shares with no signaling of concerns—Klein affirms no undisclosed adverse info. Near-term stock impact is negligible amid Rocket Lab's growth trajectory in launches and Neutron rocket development. Investors should monitor aggregate insider selling patterns and upcoming earnings for business momentum, but this filing alone warrants no action.